Logo-npj
Submitted: 04 Jun 2022
Accepted: 31 Jul 2022
ePublished: 05 Aug 2022
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Nephropharmacol. 2023;12(1): e10486.
doi: 10.34172/npj.2022.10486
  Abstract View: 8215
  PDF Download: 1104

News and Views

Nirmatrelvir, a novel medication for COVID-19 treatment

Mohammad Reza Hajian 1 ORCID logo, Hamid Reza Jahantigh 2 ORCID logo, Shahrzad Alimohammadi 3,4 ORCID logo, Zahra Mojtahedi 5 ORCID logo, Neda Kianpour 6 ORCID logo, Majid Foroutan 7* ORCID logo

1 Nickan Research Institute, Isfahan, Iran
2 Animal Health and Zoonosis PhD Course, Department of Veterinary Medicine, University of Bari, Bari, Italy
3 Doctoral School of Molecular Medicine, University of Debrecen, Debrecen, Hungary
4 Department of Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
5 School of Public Health, University of Nevada, Las Vegas, Nevada, USA
6 Department of Biotechnology, Inland Norway University of Applied Science, Hamar, Hedmark, Norway
7 Department of Internal Medicine, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran
*Corresponding Author: Corresponding author: Majid Foroutan, Email: dr_forotan@yahoo.com, , Email: dr_forotan@semums.ac.ir

Implication for health policy/practice/research/medical education:

COVID-19 is a viral disease that first emerged in December 2019, Wuhan, China. In a short time, the disease spread and the world faced with a new pandemic. Since then, great effort implanted to produce effective vaccines and medications for the disease. Nirmatrelvir (PF07321332) is a new drug developed by Pfizer, Inc for COVID-19 treatment. In this essay, we stated recent findings about Nirmatrelvir.

Please cite this paper as: Hajian MR, Jahantigh HR, Alimohammadi S, Mojtahedi Z, Kianpour N, Foroutan M. Nirmatrelvir, a novel medication for COVID-19 treatment. J Nephropharmacol. 2023;12(1):e10486. DOI: 10.34172/npj.2021.10486.

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 8216

Your browser does not support the canvas element.


PDF Download: 1104

Your browser does not support the canvas element.